Pirenzepine, cimetidine and placebo in the long-term treatment of duodenal ulceration. A comparative study.
Sixty patients with endoscopically proven healed duodenal ulcers were treated for a year with either pirenzepine (Gastrozepin; Boehringer Ingelheim) 100 mg daily, cimetidine 400 mg at night, or placebo, The monthly relapse rate (patients per month) in the first 3 months (pirenzepine 2,3, cimetidine 2,3, placebo 3,0) and in the next 9 months (pirenzepine 0,33, cimetidine 0,44, placebo 0,56) is lower for pirenzepine and cimetidine than for placebo. This trend is in favour of pirenzepine and cimetidine as effective means of keeping duodenal ulcers in remission. Asymptomatic relapses were also less common with pirenzepine (50%) and cimetidine (45%) than with placebo (64%). No serious side-effects of pirenzepine were observed during the trail.
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010276:Parasympatholytics / Q000009:adverse effects; D010879:Piperazines / Q000627:therapeutic use*; D010890:Pirenzepine; D011897:Random Allocation
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D006146:Guanidines; D010276:Parasympatholytics; D010879:Piperazines; D010890:Pirenzepine; D002927:Cimetidine